{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:39:07Z","timestamp":1792204747492,"version":"4.4.0"},"reference-count":214,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"British Heart Foundation Clinical Research Training Fellowship"},{"name":"British Heart Foundation Intermediate Clinical Fellowship"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Obesity is one of the biggest risks to public health in both developed and developing countries, and yet incidence continues to skyrocket. Being the main risk factor for a large number of life-limiting conditions, obesity has the potential to cause enormous damage unless addressed urgently. Heart failure (HF) is the most common cardiovascular disease associated with obesity. The incidence of HF overall continues to rise and mortality rates remain high, despite the rapid and significant advances in pharmacotherapy that have recently transformed the landscape of HF treatment. Both obesity and heart failure are multisystem disorders that are closely interlinked. Obesity poses the body a number of challenges, ranging from haemodynamic, to neuroendocrine, to inflammatory, to intracellular physiology. This narrative review describes the pathophysiological \u2018vicious cycle\u2019 caused by the combination of obesity and HF. Management of obesity in established heart failure has for years been a controversial topic, and yet an increasing body of evidence suggests that there are numerous benefits to managing obesity and insulin resistance in heart failure. Here, we review the existing evidence base, as well as exciting new developments, suggesting that we may finally be on the brink of a revolution in managing obesity in heart failure.<\/jats:p>","DOI":"10.1093\/cvr\/cvaf090","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:15:33Z","timestamp":1748924133000},"page":"1173-1186","source":"Crossref","is-referenced-by-count":15,"title":["Obesity and heart failure: exploring the cardiometabolic axis"],"prefix":"10.1093","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3519-5480","authenticated-orcid":false,"given":"Jennifer J","family":"Rayner","sequence":"first","affiliation":[{"name":"Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Abdesselam","sequence":"additional","affiliation":[{"name":"Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiliu","family":"Pan","sequence":"additional","affiliation":[{"name":"Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J M","family":"Lewis","sequence":"additional","affiliation":[{"name":"Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J","family":"Rider","sequence":"additional","affiliation":[{"name":"Oxford Centre for Clinical Magnetic Resonance Research, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2025073019513180500_cvaf090-B1","doi-asserted-by":"crossref","first-page":"e003921","DOI":"10.1161\/JAHA.116.003921","article-title":"Obesity and subtypes of incident cardiovascular disease","volume":"5","author":"Ndumele","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2025073019513180500_cvaf090-B2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.21037\/cdt-19-587","article-title":"Obesity-related ventricular remodelling is exacerbated in dilated and hypertrophic cardiomyopathy","volume":"10","author":"Rayner","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"key":"2025073019513180500_cvaf090-B3"},{"key":"2025073019513180500_cvaf090-B4","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/cvr\/cvab368","article-title":"Obesity increases heart failure incidence and mortality: observational and Mendelian randomization studies totalling over 1 million individuals","volume":"118","author":"Benn","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2025073019513180500_cvaf090-B5","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jacc.2016.11.081","article-title":"Relationship between physical activity, body mass index, and risk of heart failure","volume":"69","author":"Pandey","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa020245","article-title":"Obesity and the risk of heart failure","volume":"347","author":"Kenchaiah","year":"2002","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B7","author":"National Cardiac Audit Programme"},{"key":"2025073019513180500_cvaf090-B8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s12471-023-01832-w","article-title":"Cardiac rehabilitation for patients with obesity: lessons learned from the OPTICARE XL trial","volume":"32","author":"den Uijl","year":"2024","journal-title":"Neth Heart J"},{"key":"2025073019513180500_cvaf090-B9","first-page":"CD003331","article-title":"Exercise-based cardiac rehabilitation for adults with heart failure","volume":"1","author":"Long","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025073019513180500_cvaf090-B10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/clpt.2011.72","article-title":"The obesity paradox in heart failure: accepting reality and making rational decisions","volume":"90","author":"Anker","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2025073019513180500_cvaf090-B11","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/eurheartj\/ehad079","article-title":"Revisiting the obesity paradox in heart failure: what is the best anthropometric index to gauge obesity?","volume":"44","author":"Sato","year":"2023","journal-title":"Eur Heart J"},{"key":"2025073019513180500_cvaf090-B12","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(03)12892-9","article-title":"Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study","volume":"361","author":"Anker","year":"2003","journal-title":"Lancet"},{"key":"2025073019513180500_cvaf090-B13","doi-asserted-by":"crossref","first-page":"e002468","DOI":"10.1161\/JAHA.115.002468","article-title":"Weight loss in obese patients with heart failure","volume":"5","author":"Zamora","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2025073019513180500_cvaf090-B14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/CIRCULATIONAHA.123.067505","article-title":"Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial","volume":"149","author":"Kosiborod","year":"2024","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2024","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B16","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073019513180500_cvaf090-B17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcmg.2009.10.012","article-title":"The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"3","author":"Turkbey","year":"2010","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025073019513180500_cvaf090-B18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00000441-200104000-00003","article-title":"Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome","volume":"321","author":"Alpert","year":"2001","journal-title":"Am J Med Sci"},{"key":"2025073019513180500_cvaf090-B19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1161\/CIRCIMAGING.113.000532","article-title":"Relation of regional fat distribution to left ventricular structure and function","volume":"6","author":"Neeland","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025073019513180500_cvaf090-B20","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1038\/s41366-018-0263-2","article-title":"Very low calorie diets are associated with transient ventricular impairment before reversal of diastolic dysfunction in obesity","volume":"43","author":"Rayner","year":"2019","journal-title":"Int J Obes"},{"key":"2025073019513180500_cvaf090-B21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/ehjci\/jeac270","article-title":"The role of obesity-related cardiovascular remodelling in mediating incident cardiovascular outcomes: a population-based observational study","volume":"24","author":"Szabo","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025073019513180500_cvaf090-B22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/db15-0627","article-title":"Relationship between left ventricular structural and metabolic remodelling in type 2 diabetes mellitus","volume":"65","author":"Levelt","year":"2015","journal-title":"Diabetes"},{"key":"2025073019513180500_cvaf090-B23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ijo.2017.239","article-title":"The relative contribution of metabolic and structural abnormalities to diastolic dysfunction in obesity","volume":"42","author":"Rayner","year":"2017","journal-title":"Int J Obes"},{"key":"2025073019513180500_cvaf090-B24","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2003.10.062","article-title":"Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging","volume":"43","author":"Peterson","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B25","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1161\/01.CIR.0000147184.13872.0F","article-title":"Alterations of left ventricular myocardial characteristics associated with obesity","volume":"110","author":"Wong","year":"2004","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12933-018-0756-2","article-title":"Overweight and obesity impair left ventricular systolic function as measured by left ventricular ejection fraction and global longitudinal strain","volume":"17","author":"Blomstrand","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2025073019513180500_cvaf090-B27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1540-8175.2009.01024.x","article-title":"Effects of isolated obesity on left and right ventricular function: a tissue Doppler and strain rate imaging study","volume":"27","author":"Orhan","year":"2010","journal-title":"Echocardiography"},{"key":"2025073019513180500_cvaf090-B28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/echo.12164","article-title":"Severe obesity impairs systolic and diastolic heart function\u2014the significance of pulsed tissue Doppler, strain, and strain rate parameters","volume":"30","author":"Wierzbowska-Drabik","year":"2013","journal-title":"Echocardiography"},{"key":"2025073019513180500_cvaf090-B29","doi-asserted-by":"crossref","first-page":"e004396","DOI":"10.1161\/CIRCIMAGING.115.004396","article-title":"Association of central adiposity with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network study","volume":"9","author":"Selvaraj","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025073019513180500_cvaf090-B30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.21037\/qims.2020.01.16","article-title":"Left ventricular myocardial deformation: a study on diastolic function in the Chinese male population and its relationship with fat distribution","volume":"10","author":"Zhu","year":"2020","journal-title":"Quant Imaging Med Surg"},{"key":"2025073019513180500_cvaf090-B31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2014.03.014","article-title":"Impact of general and central adiposity on ventricular\u2013arterial aging in women and men","volume":"2","author":"Wohlfahrt","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2025073019513180500_cvaf090-B32","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1540-8175.2007.00484.x","article-title":"Effect of obesity on left ventricular structure and myocardial systolic function: assessment by tissue Doppler imaging and strain\/strain rate imaging","volume":"24","author":"Murat Tumuklu","year":"2007","journal-title":"Echocardiography"},{"key":"2025073019513180500_cvaf090-B33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ejhf.521","article-title":"Abdominal adiposity, general obesity, and subclinical systolic dysfunction in the elderly: a population-based cohort study","volume":"18","author":"Russo","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/ehjci\/jeab175","article-title":"Adverse right ventricular remodelling, function, and stress responses in obesity: insights from cardiovascular magnetic resonance","volume":"23","author":"Lewis","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025073019513180500_cvaf090-B35","doi-asserted-by":"crossref","first-page":"814505","DOI":"10.3389\/fcvm.2022.814505","article-title":"Regional fat distributions are associated with subclinical right ventricular dysfunction in adults with uncomplicated obesity","volume":"9","author":"Liu","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2025073019513180500_cvaf090-B36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jacc.2005.11.015","article-title":"Association of subclinical right ventricular dysfunction with obesity","volume":"47","author":"Wong","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B37","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2009.07.034","article-title":"The aging process of the heart: obesity is the main risk factor for left atrial enlargement during aging the MONICA\/KORA (monitoring of trends and determinations in cardiovascular disease\/cooperative research in the region of Augsburg) study","volume":"54","author":"Stritzke","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B38","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.amjcard.2018.11.035","article-title":"Effect of obesity on left atrial strain in persons aged 35\u201355 years (the Asklepios study)","volume":"123","author":"Chirinos","year":"2019","journal-title":"Am J Cardiol"},{"key":"2025073019513180500_cvaf090-B39","doi-asserted-by":"crossref","first-page":"e026023","DOI":"10.1161\/JAHA.122.026023","article-title":"Effect of weight loss on early left atrial myopathy in people with obesity but no established cardiovascular disease","volume":"11","author":"Deal","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025073019513180500_cvaf090-B40","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/CIRCULATIONAHA.116.024921","article-title":"Genetic obesity and the risk of atrial fibrillation: causal estimates from Mendelian randomization","volume":"135","author":"Chatterjee","year":"2017","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40119-023-00317-6","article-title":"Effect of obesity duration and BMI trajectories on cardiovascular disease: a narrative review","volume":"12","author":"Amani-Beni","year":"2023","journal-title":"Cardiol Ther"},{"key":"2025073019513180500_cvaf090-B42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/ejhf.2377","article-title":"Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity","volume":"24","author":"Obokata","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B43","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1161\/CIRCULATIONAHA.111.039586","article-title":"Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction","volume":"126","author":"Greulich","year":"2012","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B44","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1161\/01.CIR.0000099542.57313.C5","article-title":"Human epicardial adipose tissue is a source of inflammatory mediators","volume":"108","author":"Mazurek","year":"2003","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B45","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.jacc.2015.09.071","article-title":"Normalization of visceral fat and complete reversal of cardiovascular remodeling accompany gastric bypass, not banding","volume":"66","author":"Rayner","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1196\/annals.1302.017","article-title":"Linking gene expression to function: metabolic flexibility in the normal and diseased heart","volume":"1015","author":"Taegtmeyer","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2025073019513180500_cvaf090-B47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1042\/bj3110161","article-title":"Failure of insulin-regulated recruitment of the glucose transporter GLUT4 in cardiac muscle of obese Zucker rats is associated with alterations of small-molecular-mass GTP-binding proteins","volume":"311","author":"Uphues","year":"1995","journal-title":"Biochem J"},{"key":"2025073019513180500_cvaf090-B48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev Med"},{"key":"2025073019513180500_cvaf090-B49","doi-asserted-by":"crossref","first-page":"16710","DOI":"10.1074\/jbc.273.27.16710","article-title":"Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner","volume":"273","author":"Motojima","year":"1998","journal-title":"J Biol Chem"},{"key":"2025073019513180500_cvaf090-B50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0952-3278(97)90491-9","article-title":"Long-term effects of fatty acids on cell viability and gene expression of neonatal cardiac myocytes","volume":"57","author":"Van Bilsen","year":"1997","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2025073019513180500_cvaf090-B51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-2275(20)32072-1","article-title":"Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes","volume":"41","author":"van der Lee","year":"2000","journal-title":"J Lipid Res"},{"key":"2025073019513180500_cvaf090-B52","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/S0021-9258(18)42645-2","article-title":"Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms","volume":"267","author":"Distel","year":"1992","journal-title":"J Biol Chem"},{"key":"2025073019513180500_cvaf090-B53","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1152\/physrev.1992.72.4.881","article-title":"Fatty acid homeostasis in the normoxic and ischemic heart","volume":"72","author":"van der Vusse","year":"1992","journal-title":"Physiol Rev"},{"key":"2025073019513180500_cvaf090-B54","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.2337\/diabetes.53.7.1655","article-title":"Enhanced sarcolemmal FAT\/CD36 content and triacylglycerol storage in cardiac myocytes from obese Zucker rats","volume":"53","author":"Coort","year":"2004","journal-title":"Diabetes"},{"key":"2025073019513180500_cvaf090-B55","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.2337\/db14-1560","article-title":"Increasing pyruvate dehydrogenase flux as a treatment for diabetic cardiomyopathy: a combined 13C hyperpolarized magnetic resonance and echocardiography study","volume":"64","author":"Le Page","year":"2015","journal-title":"Diabetes"},{"key":"2025073019513180500_cvaf090-B56","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0952-3278(99)80009-X","article-title":"The role of the peroxisome proliferator-activated receptor alpha (PPAR alpha) in the control of cardiac lipid metabolism","volume":"60","author":"Djouadi","year":"1999","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2025073019513180500_cvaf090-B57","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1073\/pnas.97.4.1784","article-title":"Lipotoxic heart disease in obese rats: implications for human obesity","volume":"97","author":"Zhou","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025073019513180500_cvaf090-B58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1146\/annurev.med.53.082901.104057","article-title":"Lipotoxic diseases","volume":"53","author":"Unger","year":"2002","journal-title":"Annu Rev Med"},{"key":"2025073019513180500_cvaf090-B59","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jcmg.2014.12.019","article-title":"Evidence of a direct effect of myocardial steatosis on LV hypertrophy and diastolic dysfunction in adult and adolescent obesity","volume":"8","author":"Banerjee","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"2025073019513180500_cvaf090-B60","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2014an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B61","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/CIRCULATIONAHA.111.069518","article-title":"Effects of catecholamine stress on diastolic function and myocardial energetics in obesity","volume":"125","author":"Rider","year":"2012","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B62","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1161\/CIRCULATIONAHA.119.042770","article-title":"Myocardial energetics in obesity: enhanced ATP delivery through creatine kinase with blunted stress response","volume":"141","author":"Rayner","year":"2020","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B63","first-page":"868","article-title":"Obesity modifies the energetic phenotype of dilated cardiomyopathy","volume":"43","author":"Rayner","year":"2022","journal-title":"Eur Heart J"},{"key":"2025073019513180500_cvaf090-B64","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/archinte.1981.00340010073016","article-title":"Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity","volume":"141","author":"Messerli","year":"1981","journal-title":"Arch Intern Med"},{"key":"2025073019513180500_cvaf090-B65","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"key":"2025073019513180500_cvaf090-B66","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/HYPERTENSIONAHA.115.06736","article-title":"Leptin mediates high-fat diet sensitization of angiotensin II-elicited hypertension by upregulating the brain renin-angiotensin system and inflammation","volume":"67","author":"Xue","year":"2016","journal-title":"Hypertension"},{"key":"2025073019513180500_cvaf090-B67","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.cardiores.2005.11.022","article-title":"Direct effects of leptin on size and extracellular matrix components of human pediatric ventricular myocytes","volume":"69","author":"Madani","year":"2006","journal-title":"Cardiovasc Res"},{"key":"2025073019513180500_cvaf090-B68","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jacc.2008.05.060","article-title":"Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease","volume":"52","author":"Martin","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B69","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","article-title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase","volume":"8","author":"Yamauchi","year":"2002","journal-title":"Nat Med"},{"key":"2025073019513180500_cvaf090-B70","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1161\/CIRCULATIONAHA.104.530972","article-title":"Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure","volume":"112","author":"Kistorp","year":"2005","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B71","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrcardio.2009.55","article-title":"Obesity, inflammation, and atherosclerosis","volume":"6","author":"Rocha","year":"2009","journal-title":"Nat Rev Cardiol"},{"key":"2025073019513180500_cvaf090-B72","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate immunity and the failing heart: the cytokine hypothesis revisited","volume":"116","author":"Mann","year":"2015","journal-title":"Circ Res"},{"key":"2025073019513180500_cvaf090-B73","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/CIRCRESAHA.121.318160","article-title":"Reverse remodeling with left ventricular assist devices","volume":"128","author":"Burkhoff","year":"2021","journal-title":"Circ Res"},{"key":"2025073019513180500_cvaf090-B74","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.diabres.2004.11.007","article-title":"Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6","volume":"69","author":"Park","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073019513180500_cvaf090-B75","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2337\/diab.43.11.1271","article-title":"Tumor necrosis factor alpha: a key component of the obesity\u2013diabetes link","volume":"43","author":"Hotamisligil","year":"1994","journal-title":"Diabetes"},{"key":"2025073019513180500_cvaf090-B76","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1172\/JCI57559","article-title":"Apoe regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice","volume":"121","author":"Murphy","year":"2011","journal-title":"J Clin Invest"},{"key":"2025073019513180500_cvaf090-B77","doi-asserted-by":"crossref","first-page":"e0159350","DOI":"10.1371\/journal.pone.0159350","article-title":"Circulating blood monocyte subclasses and lipid-laden adipose tissue macrophages in human obesity","volume":"11","author":"Pecht","year":"2016","journal-title":"PLoS One"},{"key":"2025073019513180500_cvaf090-B78","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1038\/oby.2009.113","article-title":"Neutrophil activation in morbid obesity, chronic activation of acute inflammation","volume":"17","author":"Nijhuis","year":"2009","journal-title":"Obesity"},{"key":"2025073019513180500_cvaf090-B79","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/s41577-018-0065-8","article-title":"Cardioimmunology: the immune system in cardiac homeostasis and disease","volume":"18","author":"Swirski","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025073019513180500_cvaf090-B80","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cell.2020.08.031","article-title":"A network of macrophages supports mitochondrial homeostasis in the heart","volume":"183","author":"Nicol\u00e1s-\u00c1vila","year":"2020","journal-title":"Cell"},{"key":"2025073019513180500_cvaf090-B81","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cell.2017.03.050","article-title":"Macrophages facilitate electrical conduction in the heart","volume":"169","author":"Hulsmans","year":"2017","journal-title":"Cell"},{"key":"2025073019513180500_cvaf090-B82","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/CIRCRESAHA.116.309001","article-title":"Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure","volume":"119","author":"Sager","year":"2016","journal-title":"Circ Res"},{"key":"2025073019513180500_cvaf090-B83","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41591-018-0059-x","article-title":"The human heart contains distinct macrophage subsets with divergent origins and functions","volume":"24","author":"Bajpai","year":"2018","journal-title":"Nat Med"},{"key":"2025073019513180500_cvaf090-B84","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/CIRCRESAHA.119.312321","article-title":"Obesity, hypertension, and cardiac dysfunction: novel roles of immunometabolism in macrophage activation and inflammation","volume":"126","author":"Mouton","year":"2020","journal-title":"Circ Res"},{"key":"2025073019513180500_cvaf090-B85","doi-asserted-by":"crossref","first-page":"H1366","DOI":"10.1152\/ajpheart.00111.2012","article-title":"Macrophages modulate cardiac function in lipotoxic cardiomyopathy","volume":"303","author":"Schilling","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2025073019513180500_cvaf090-B86","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tcm.2014.09.005","article-title":"Impact of obesity on cardiac metabolism, fibrosis, and function","volume":"25","author":"Mahajan","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"2025073019513180500_cvaf090-B87","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbalip.2016.11.003","article-title":"Palmitate promotes inflammatory responses and cellular senescence in cardiac fibroblasts","volume":"1862","author":"Sokolova","year":"2017","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"2025073019513180500_cvaf090-B88","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B89","doi-asserted-by":"crossref","first-page":"e005036","DOI":"10.1161\/CIRCHEARTFAILURE.118.005036","article-title":"IL-1 Blockade in patients with heart failure with preserved ejection fraction","volume":"11","author":"Van Tassell","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2025073019513180500_cvaf090-B90","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cardiores.2005.10.001","article-title":"The role of natriuretic peptides in cardioprotection","volume":"69","author":"Nishikimi","year":"2006","journal-title":"Cardiovasc Res"},{"key":"2025073019513180500_cvaf090-B91","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jacc.2016.10.001","article-title":"NT-proBNP: the gold standard biomarker in heart failure","volume":"68","author":"McKie","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B92","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2025073019513180500_cvaf090-B93","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10741-011-9249-z","article-title":"The paradox of low BNP levels in obesity","volume":"17","author":"Clerico","year":"2012","journal-title":"Heart Fail Rev"},{"key":"2025073019513180500_cvaf090-B94","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.jacc.2018.02.071","article-title":"B-type natriuretic peptide levels and mortality in patients with and without heart failure","volume":"71","author":"York","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B95","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2003.10.066","article-title":"Obesity and suppressed B-type natriuretic peptide levels in heart failure","volume":"43","author":"Mehra","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B96","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ejheart.2005.04.003","article-title":"Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of aetiology","volume":"7","author":"Rivera","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B97","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jacc.2013.03.038","article-title":"Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile","volume":"62","author":"Neeland","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B98","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.trsl.2017.06.001","article-title":"Modulation of natriuretic peptide receptors in human adipose tissue: molecular mechanisms behind the \u201cnatriuretic handicap\u201d in morbidly obese patients","volume":"186","author":"Gentili","year":"2017","journal-title":"Transl Res"},{"key":"2025073019513180500_cvaf090-B99","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/ijo.2010.227","article-title":"Neprilysin, obesity and the metabolic syndrome","volume":"35","author":"Standeven","year":"2011","journal-title":"Int J Obes"},{"key":"2025073019513180500_cvaf090-B100","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.2337\/db09-0393","article-title":"Natriuretic peptides\/cGMP\/cGMP-dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity","volume":"58","author":"Miyashita","year":"2009","journal-title":"Diabetes"},{"key":"2025073019513180500_cvaf090-B101","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B102","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ahj.2005.10.011","article-title":"How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study","volume":"151","author":"Daniels","year":"2006","journal-title":"Am Heart J"},{"key":"2025073019513180500_cvaf090-B103","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1001\/archinte.167.4.400","article-title":"Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea","volume":"167","author":"Bayes-Genis","year":"2007","journal-title":"Arch Intern Med"},{"key":"2025073019513180500_cvaf090-B104","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/ejhf.792","article-title":"Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial","volume":"19","author":"Olivier","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjcard.2021.01.018","article-title":"Effect of obesity on response to spironolactone in patients with heart failure with preserved ejection fraction","volume":"146","author":"Elkholey","year":"2021","journal-title":"Am J Cardiol"},{"key":"2025073019513180500_cvaf090-B106","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ehf2.14068","article-title":"Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study","volume":"10","author":"Zhou","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2025073019513180500_cvaf090-B107","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2025073019513180500_cvaf090-B108","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/10742484211024441","article-title":"Association of body mass index with clinical outcomes in patients with heart failure with reduced ejection fraction treated with sacubitril\/valsartan","volume":"26","author":"Kido","year":"2021","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2025073019513180500_cvaf090-B109","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/eurheartj\/ehad083","article-title":"Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox","volume":"44","author":"Butt","year":"2023","journal-title":"Eur Heart J"},{"key":"2025073019513180500_cvaf090-B110","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jacbts.2020.07.006","article-title":"Differential effects of sacubitril\/valsartan on diastolic function in mice with obesity-related metabolic heart disease","volume":"5","author":"Croteau","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2025073019513180500_cvaf090-B111","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B112","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B113","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B114","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B115","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus","volume":"139","author":"Figtree","year":"2019","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B116","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.050255","article-title":"Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial","volume":"142","author":"Cosentino","year":"2020","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B117","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B118","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B119","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","article-title":"The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial","volume":"28","author":"Spertus","year":"2022","journal-title":"Nat Med"},{"key":"2025073019513180500_cvaf090-B120","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B121","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B122","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2337\/db23-0448","article-title":"Role of glycosuria in SGLT2 inhibitor-induced cardiorenal protection: a mechanistic analysis of the CREDENCE trial","volume":"73","author":"Ferrannini","year":"2024","journal-title":"Diabetes"},{"key":"2025073019513180500_cvaf090-B123","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.12578","article-title":"Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition","volume":"18","author":"Rajeev","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2025073019513180500_cvaf090-B124","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity"},{"key":"2025073019513180500_cvaf090-B125","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B126","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.crphys.2022.05.003","article-title":"Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6\/J mice","volume":"5","author":"Xie","year":"2022","journal-title":"Curr Res Physiol"},{"key":"2025073019513180500_cvaf090-B127","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2018.07.006","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors","volume":"3","author":"Verma","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2025073019513180500_cvaf090-B128","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/jcm8111814","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","volume":"8","author":"Iannantuoni","year":"2019","journal-title":"J Clin Med"},{"key":"2025073019513180500_cvaf090-B129","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"2025073019513180500_cvaf090-B130","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ajh\/hpz016","article-title":"Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload","volume":"32","author":"Shi","year":"2019","journal-title":"Am J Hypertens"},{"key":"2025073019513180500_cvaf090-B131","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","article-title":"Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction","volume":"4","author":"Connelly","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"2025073019513180500_cvaf090-B132","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2025073019513180500_cvaf090-B133","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.2337\/db21-0270","article-title":"Empagliflozin treatment is associated with improvements in cardiac energetics and function and reductions in myocardial cellular volume in patients with type 2 diabetes","volume":"70","author":"Thirunavukarasu","year":"2021","journal-title":"Diabetes"},{"key":"2025073019513180500_cvaf090-B134","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2025073019513180500_cvaf090-B135","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2337\/db20-0921","article-title":"SGLT2 inhibition does not affect myocardial fatty acid oxidation or uptake, but reduces myocardial glucose uptake and blood flow in individuals with type 2 diabetes: a randomized double-blind, placebo-controlled crossover trial","volume":"70","author":"Lauritsen","year":"2021","journal-title":"Diabetes"},{"key":"2025073019513180500_cvaf090-B136","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B137","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B138","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1093\/eurheartj\/ehab530","article-title":"Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial","volume":"43","author":"Oyama","year":"2022","journal-title":"Eur Heart J"},{"key":"2025073019513180500_cvaf090-B139","doi-asserted-by":"crossref","first-page":"110094","DOI":"10.1016\/j.diabres.2022.110094","article-title":"Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes","volume":"192","author":"Suissa","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073019513180500_cvaf090-B140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ejhf.2728","article-title":"Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B141","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/ejhf.2308","article-title":"Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index","volume":"23","author":"Adamson","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B142","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1093\/eurheartj\/ehac481","article-title":"Dapagliflozin for heart failure according to body mass index: the DELIVER trial","volume":"43","author":"Adamson","year":"2022","journal-title":"Eur Heart J"},{"key":"2025073019513180500_cvaf090-B143","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlc.2022.06.094","article-title":"Impact of baseline body mass index on key primary outcome in the EMPEROR-Preserved trial","author":"Nicholls","year":"2022"},{"key":"2025073019513180500_cvaf090-B144","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ejhf.3221","article-title":"Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: principal findings and meta-analysis with the DELIVER trial","volume":"26","author":"Sattar","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B145","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.jacc.2009.07.054","article-title":"Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function","volume":"54","author":"de las Fuentes","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B146","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF03324798","article-title":"Effects of weight loss on ventricular systolic and diastolic functions and left ventricular mass assessed by tissue Doppler imaging in obese geriatric women: preliminary report","volume":"22","author":"Varli","year":"2010","journal-title":"Aging Clin Exp Res"},{"key":"2025073019513180500_cvaf090-B147","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11695-008-9645-1","article-title":"The impact of weight loss on cardiac structure and function in obese patients","volume":"19","author":"Syed","year":"2009","journal-title":"Obes Surg"},{"key":"2025073019513180500_cvaf090-B148","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1177\/2047487314541731","article-title":"Weight loss and progressive left ventricular remodelling: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"22","author":"Shah","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2025073019513180500_cvaf090-B149","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0002-9149(97)00505-5","article-title":"Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss","volume":"80","author":"Alpert","year":"1997","journal-title":"Am J Cardiol"},{"key":"2025073019513180500_cvaf090-B150","doi-asserted-by":"crossref","first-page":"1092777","DOI":"10.3389\/fendo.2023.1092777","article-title":"Changes in epicardial and visceral adipose tissue depots following bariatric surgery and their effect on cardiac geometry","volume":"14","author":"Henry","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025073019513180500_cvaf090-B151","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10554-013-0302-y","article-title":"Sustained cardiac remodeling after a short-term very low calorie diet in type 2 diabetes mellitus patients","volume":"30","author":"Jonker","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"2025073019513180500_cvaf090-B152","doi-asserted-by":"crossref","first-page":"H1174","DOI":"10.1152\/ajpheart.01236.2007","article-title":"The effects of caloric restriction- and exercise-induced weight loss on left ventricular diastolic function","volume":"294","author":"Riordan","year":"2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2025073019513180500_cvaf090-B153","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jacc.2008.04.068","article-title":"Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function","volume":"52","author":"Hammer","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B154","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2019.04.019","article-title":"Hemodynamic effects of weight loss in obesity: a systematic review and meta-analysis","volume":"7","author":"Reddy","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2025073019513180500_cvaf090-B155","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/oby.2011.390","article-title":"Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients","volume":"20","author":"Snel","year":"2012","journal-title":"Obesity"},{"key":"2025073019513180500_cvaf090-B156","doi-asserted-by":"crossref","first-page":"e009241","DOI":"10.1161\/CIRCIMAGING.119.009241","article-title":"Weight loss affects intramyocardial glucose metabolism in obese humans","volume":"12","author":"Madigan","year":"2019","journal-title":"Circ Cardiovasc Imaging"},{"key":"2025073019513180500_cvaf090-B157","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/oby.2011.186","article-title":"Myocardial oxygen consumption change predicts left ventricular relaxation improvement in obese humans after weight loss","volume":"19","author":"Lin","year":"2011","journal-title":"Obesity"},{"key":"2025073019513180500_cvaf090-B158","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.ijcard.2012.03.104","article-title":"Moderate dietary weight loss reduces myocardial steatosis in obese and overweight women","volume":"167","author":"Utz","year":"2013","journal-title":"Int J Cardiol"},{"key":"2025073019513180500_cvaf090-B159","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s10554-012-0174-6","article-title":"Effects of weight loss on myocardial energetics and diastolic function in obesity","volume":"29","author":"Rider","year":"2013","journal-title":"Int J Cardiovasc Imaging"},{"key":"2025073019513180500_cvaf090-B160","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1136\/heartjnl-2012-301778","article-title":"Bariatric surgery and cardiovascular outcomes: a systematic review","volume":"98","author":"Vest","year":"2012","journal-title":"Heart"},{"key":"2025073019513180500_cvaf090-B161","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s11695-015-1866-5","article-title":"The effects of bariatric surgery on cardiac structure and function: a systematic review of cardiac imaging outcomes","volume":"26","author":"Aggarwal","year":"2016","journal-title":"Obes Surg"},{"key":"2025073019513180500_cvaf090-B162","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ajh\/hpt215","article-title":"Effects of bariatric surgery on cardiac structure and function: a systematic review and meta-analysis","volume":"27","author":"Cuspidi","year":"2014","journal-title":"Am J Hypertens"},{"key":"2025073019513180500_cvaf090-B163","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.cardfail.2017.05.005","article-title":"Risk of heart failure in obese patients with and without bariatric surgery in Sweden\u2014a registry-based study","volume":"23","author":"Persson","year":"2017","journal-title":"J Card Fail"},{"key":"2025073019513180500_cvaf090-B164","doi-asserted-by":"crossref","first-page":"e019323","DOI":"10.1161\/JAHA.120.019323","article-title":"Potential effects of bariatric surgery on the incidence of heart failure and atrial fibrillation in patients with type 2 diabetes mellitus and obesity and on mortality in patients with preexisting heart failure: a nationwide, matched, observational cohort study","volume":"10","author":"H\u00f6skuldsd\u00f3ttir","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025073019513180500_cvaf090-B165","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.116.025629","article-title":"Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment","volume":"135","author":"Sundstr\u00f6m","year":"2017","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B166","doi-asserted-by":"crossref","first-page":"e000910","DOI":"10.1136\/openhrt-2018-000910","article-title":"Bariatric surgery among patients with heart failure: a systematic review and meta-analysis","volume":"5","author":"Berger","year":"2018","journal-title":"Open Heart"},{"key":"2025073019513180500_cvaf090-B167","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Look","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025073019513180500_cvaf090-B168","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.13888","article-title":"Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: an updated meta-analysis and subgroup analysis of randomized controlled trials","volume":"22","author":"Mannucci","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2025073019513180500_cvaf090-B169","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.numecd.2020.03.013","article-title":"Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"30","author":"Nreu","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025073019513180500_cvaf090-B170","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B171","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"key":"2025073019513180500_cvaf090-B172","first-page":"e010161","article-title":"A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction","volume":"16","author":"Brubaker","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2025073019513180500_cvaf090-B173","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/obr.12707","article-title":"Effects of intentional weight loss in patients with obesity and heart failure: a systematic review","volume":"19","author":"McDowell","year":"2018","journal-title":"Obes Rev"},{"key":"2025073019513180500_cvaf090-B174","doi-asserted-by":"crossref","first-page":"A11064","DOI":"10.1161\/circ.144.suppl_1.11064","article-title":"Intentional weight loss as a novel treatment for heart failure with preserved ejection fraction","volume":"144","author":"Hundertmark","year":"2021","journal-title":"Circulation"},{"key":"2025073019513180500_cvaf090-B175","doi-asserted-by":"crossref","first-page":"e022930","DOI":"10.1161\/JAHA.121.022930","article-title":"Pragmatic weight management program for patients with obesity and heart failure with preserved ejection fraction","volume":"10","author":"El Hajj","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025073019513180500_cvaf090-B176","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/clc.20315","article-title":"Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure","volume":"31","author":"Ramani","year":"2008","journal-title":"Clin Cardiol"},{"key":"2025073019513180500_cvaf090-B177","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s11695-013-0953-8","article-title":"Impact of bariatric surgery on quality of life, functional capacity, and symptoms in patients with heart failure","volume":"23","author":"Miranda","year":"2013","journal-title":"Obes Surg"},{"key":"2025073019513180500_cvaf090-B178","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jacc.2015.12.016","article-title":"Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based, self-controlled series","volume":"67","author":"Shimada","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B179","doi-asserted-by":"crossref","first-page":"e002260","DOI":"10.1161\/CIRCHEARTFAILURE.115.002260","article-title":"Clinical and echocardiographic outcomes after bariatric surgery in obese patients with left ventricular systolic dysfunction","volume":"9","author":"Vest","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2025073019513180500_cvaf090-B180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.soard.2018.12.030","article-title":"Impact of prior bariatric surgery on outcomes of hospitalized patients with heart failure: a population-based study","volume":"15","author":"Han","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"2025073019513180500_cvaf090-B181","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.soard.2019.03.021","article-title":"Impact of bariatric surgery on heart failure mortality","volume":"15","author":"Aleassa","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"2025073019513180500_cvaf090-B182","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.soard.2018.04.005","article-title":"Laparoscopic sleeve gastrectomy in patients with heart failure and left ventricular assist devices as a bridge to transplant","volume":"14","author":"Hawkins","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"2025073019513180500_cvaf090-B183","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.transproceed.2012.10.036","article-title":"Bariatric surgery in severe obesity and end-stage heart failure with mechanical circulatory support as a bridge to successful heart transplantation: a case report","volume":"45","author":"Caceres","year":"2013","journal-title":"Transplant Proc"},{"key":"2025073019513180500_cvaf090-B184","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.soard.2014.04.003","article-title":"Laparoscopic sleeve gastrectomy in morbidly obese patients with end-stage heart failure and left ventricular assist device: medium-term results","volume":"11","author":"Chaudhry","year":"2015","journal-title":"Surg Obes Relat Dis"},{"key":"2025073019513180500_cvaf090-B185","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.gassur.2024.02.013","article-title":"A second chance for a new heart? The role of metabolic and bariatric surgery in patients with end-stage heart failure","volume":"28","author":"Palenzuela","year":"2024","journal-title":"J Gastrointest Surg"},{"key":"2025073019513180500_cvaf090-B186","volume-title":"Bariatric Surgery for the Reduction of Cardiovascular Events: Overview and Design","author":"Wong","year":"2023"},{"key":"2025073019513180500_cvaf090-B187","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/j.1476-5381.2009.00376.x","article-title":"Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?","volume":"157","author":"Grieve","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2025073019513180500_cvaf090-B188","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1111\/j.1476-5381.2011.01714.x","article-title":"Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts","volume":"165","author":"Axelsen","year":"2012","journal-title":"Br J Pharmacol"},{"key":"2025073019513180500_cvaf090-B189","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2016.01.008","article-title":"Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction","volume":"4","author":"Lepore","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2025073019513180500_cvaf090-B190","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"2025073019513180500_cvaf090-B191","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B192","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/dom.14997","article-title":"Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025073019513180500_cvaf090-B193","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/ejhf.2670","article-title":"Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial","volume":"24","author":"Branch","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B194","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ehf2.12334","article-title":"Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial","volume":"5","author":"Sharma","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2025073019513180500_cvaf090-B195","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4\u2005mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"2025073019513180500_cvaf090-B196","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","article-title":"Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial","volume":"29","author":"Wadden","year":"2023","journal-title":"Nat Med"},{"key":"2025073019513180500_cvaf090-B197","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B198","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"2025073019513180500_cvaf090-B199","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B200","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"2025073019513180500_cvaf090-B201","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"2025073019513180500_cvaf090-B202","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B203","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials","volume":"29","author":"Neves","year":"2023","journal-title":"J Card Fail"},{"key":"2025073019513180500_cvaf090-B204","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/dom.14862","article-title":"Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: a post hoc analysis of the FIGHT trial","volume":"25","author":"Neves","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025073019513180500_cvaf090-B205","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ejhf.3478","article-title":"Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: the EXSCEL trial","volume":"27","author":"Neves","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B206","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26 Suppl 4","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2025073019513180500_cvaf090-B207","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ejhf.1304","article-title":"Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)","volume":"20","author":"Emami","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B208","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction","volume":"82","author":"Butler","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025073019513180500_cvaf090-B209","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"2025073019513180500_cvaf090-B210","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1136\/heartjnl-2023-322459","article-title":"Body mass index and survival in people with heart failure","volume":"109","author":"Jones","year":"2023","journal-title":"Heart"},{"key":"2025073019513180500_cvaf090-B211","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.mayocp.2012.11.020","article-title":"Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure","volume":"88","author":"Lavie","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"2025073019513180500_cvaf090-B212","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/eurheartj\/ehad764","article-title":"Anthropometric measures and long-term mortality in non-ischaemic heart failure with reduced ejection fraction: questioning the obesity paradox","volume":"45","author":"Butt","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2025073019513180500_cvaf090-B213","doi-asserted-by":"crossref","first-page":"109805","DOI":"10.1016\/j.diabres.2022.109805","article-title":"Associations of BMI with mortality in HFpEF patients with concomitant diabetes with insulin versus non-insulin treatment","volume":"185","author":"Ye","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073019513180500_cvaf090-B214","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10741-013-9406-7","article-title":"Anatomy of the obesity paradox in heart failure","volume":"19","author":"Guglin","year":"2014","journal-title":"Heart Fail Rev"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cardiovascres\/advance-article-pdf\/doi\/10.1093\/cvr\/cvaf090\/63422171\/cvaf090.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/121\/8\/1173\/63422171\/cvaf090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article-pdf\/121\/8\/1173\/63422171\/cvaf090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T23:52:09Z","timestamp":1753919529000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/121\/8\/1173\/8155656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":214,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,3]]},"published-print":{"date-parts":[[2025,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvaf090","relation":{},"ISSN":["0008-6363","1755-3245"],"issn-type":[{"value":"0008-6363","type":"print"},{"value":"1755-3245","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,3]]}}}